A1 Refereed original research article in a scientific journal
Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment A Randomized Trial
Authors: Yves Dauvilliers, Johan Verbraecken, Markku Partinen, Jan Hedner, Tarja Saaresranta, Ognian Georgiev, Rumen Tiholov, Isabelle Lecomte, Renaud Tamisier, Patrick Lévy, Catherine Scart-Gres, Jeanne-Marie Lecomte, ean-Charles Schwartz, Jean-Louis Pépin; on behalf of the HAROSA II Study Group
Publisher: AMER THORACIC SOC
Publication year: 2020
Journal: American Journal of Respiratory and Critical Care Medicine
Journal name in source: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Journal acronym: AM J RESP CRIT CARE
Volume: 201
Issue: 9
First page : 1135
Last page: 1145
Number of pages: 11
ISSN: 1073-449X
eISSN: 1535-4970
DOI: https://doi.org/10.1164/rccm.201907-1284OC
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/50118717
Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome.Objectives: To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-promoting effects, for the treatment of daytime sleepiness in patients with moderate to severe obstructive sleep apnea refusing continuous positive airway pressure treatment.Methods: In an international, multicenter, double-blind, randomized (3:1), placebo-controlled, parallel-design trial, pitolisant was individually titrated at up to 20 mgld over 12 weeks. The primary endpoint was the change in the Epworth Sleepiness Scale score. Key secondary endpoints were maintenance of wakefulness assessed on the basis of the Oxford Sleep Resistance test, safety, Clinical Global Impression of severity, patient's global opinion, EuroQol quality-of-life questionnaire, and Pichot fatigue questionnaire.Measurements and Main Results: A total of 268 patients with obstructive sleep apnea (75% male; mean age, 52 yr; apnea-hypopnea index, 49/h; baseline sleepiness score, 15.7) were randomized (200 to pitolisant and 68 to placebo) and analyzed on an intention-to-treat basis. The Epworth Sleepiness Scale score was reduced more with pitolisant than with placebo (-2.8; 95% confidence interval, -4.0 to -1.5; P < 0.001). Wake maintenance tests were not improved. The Pichot fatigue score was reduced with pitolisant. The overall impact of pitolisant was confirmed by both physicians' and patients' questionnaires. Adverse event incidence, mainly headache, insomnia, nausea, and vertigo, was similar in the pitolisant and placebo groups (29.5% and 25.4%, respectively), with no cardiovascular or other significant safety concerns.Conclusions: Pitolisant significantly reduced self-reported daytime sleepiness and fatigue and improved patient-reported outcomes and physician disease severity assessment in sleepy patients with obstructive sleep apnea refusing or nonadherent to continuous positive airway pressure.
Downloadable publication This is an electronic reprint of the original article. |  |
